The letter responds to comment on: Anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study. - Université de Lille
Article Dans Une Revue European Journal of Cancer Année : 2022

The letter responds to comment on: Anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study.

Domaines

Sciences du Vivant [q-bio]

LillOA Université de Lille  : Connectez-vous pour contacter le contributeur

https://hal.univ-lille.fr/hal-04382585

Soumis le : mardi 9 janvier 2024-14:37:25

Dernière modification le : mardi 4 juin 2024-12:18:04

Fichier non déposé

Dates et versions

hal-04382585 , version 1 (09-01-2024)

Identifiants

Citer

Marion Panhaleux, David Launay, Nicolas Penel, Olivier Lambotte, Alexandra Forestier. The letter responds to comment on: Anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study.. European Journal of Cancer, 2022, European Journal of Cancer, ⟨10.1016/j.ejca.2022.01.021⟩. ⟨hal-04382585⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

UNIV-LILLE
8 Consultations
0 Téléchargements

Altmetric

Partager

More